Use of allogeneic canned osteoplastic drugs for the treatment of chronic periodontitis

Abstract

BACKGROUND: Despite significant scientific advancements in the development of new methods for the diagnosis and treatment of caries and periodontal diseases using modern technologies, medications and restorative materials, the incidence of complicated caries has increased in recent years. This can be attributed to poor efficiency with regard to dental examinations, particularly in school classrooms.
 AIM: To study the clinical efficacy of allogeneic osteoplastic drugs such as Kostma, Deprotex, and Orgamax in the treatment of chronic periodontitis.
 MATERIAL AND METHODS: The study sample included 135 patients diagnosed with chronic periodontitis who underwent endodontic treatment using allogeneic drugs with osteoplastic and antimicrobial properties. Of these, 36 patients underwent treatment using bone, 46 were treated with Deprotex, and 53 received Orgamax. Drug efficacy was compared using osteo-densitometry, and active regeneration and replacement of the defect with newly formed bone tissue was seen to take place. Orgamax was seen to induce reduction of the periapical focus over a shorter duration when compared to the others. Complications of an inflammatory nature were observed in 18 patients, of which 8 patients underwent tooth extraction and 10 underwent repeated treatment. Twelve patients exhibited no bone regeneration in the defect, and a total of 98 patients presented with favorable treatment outcomes (characterized by restoration of the periapical structure of bone tissue) over a period of 3 years.
 CONCLUSION: Endodontic treatment of chronic destructive periodontitis using allogeneic drugs such as Kostma, Deprotex, and Orgamax, which have antimicrobial and osteoplastic properties, facilitates bone tissue regeneration in the periapical defect, reduces the number of inflammatory complications and relapses, increases efficiency, and improves long-term treatment outcomes.